Elasmogen develops soloMERs®, a proprietary biologics platform that creates high-affinity, selective therapeutic proteins targeting autoimmune diseases and cancer. This technology enables the rapid reformatting of biologics to produce multi-functional therapeutics, addressing the need for effective treatment options in these challenging medical areas.
Funding
$9.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional antibody-based therapeutics face challenges in targeting certain disease mechanisms due to their large size and complex structure, which can limit tissue penetration and binding to specific epitopes. This can result in suboptimal efficacy and challenges in developing treatments for autoimmune diseases and cancer.
Solution
Elasmogen leverages its proprietary soloMER platform to develop a new class of therapeutic proteins with enhanced target specificity and tissue penetration. soloMERs are single-chain proteins derived from shark VNARs (variable new antigen receptors), which are significantly smaller and more robust than traditional antibodies. This unique architecture allows for rapid reformatting and the creation of multi-functional therapeutics with differentiated binding interactions and novel mechanisms of action. The soloMER platform enables the development of targeted therapies for autoimmune diseases and cancer, overcoming limitations associated with conventional antibody-based approaches.
Target Audience
Elasmogen's primary customers are pharmaceutical companies and research institutions focused on developing novel therapeutics for autoimmune diseases, cancer, and inflammatory conditions.
Features
- soloMERs are approximately one-tenth the size of traditional antibodies, facilitating improved tissue penetration and access to previously inaccessible drug targets.
- The VNAR scaffold provides a highly stable and versatile framework for protein engineering and rapid generation of diverse therapeutic formats.
- Multi-valent formats, such as Quad-X and Quad-Y, enhance binding avidity and specificity for improved therapeutic efficacy.
- The platform supports the development of bispecific antibody drug conjugates (ADCs) with enhanced activity and selectivity.
- soloMERs can be delivered through alternative routes of administration, including direct nasal or throat delivery.
- The technology is protected by a robust and layered IP portfolio covering the generation, humanization, half-life extension, products, and product formats.